All Stories

  1. A technical and clinical evaluation of a new assay for inhibin A and its use in second trimester Down syndrome screening
  2. First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation
  3. Screening for Down syndrome
  4. First trimester detection of trisomy 16 using combined biochemical and ultrasound screening
  5. First trimester maternal serum alpha-fetoprotein is not raised in pregnancies with open spina bifida
  6. First trimester maternal serum placental growth factor levels in twin pregnancies
  7. Accuracy of self‐reported smoking status in first trimester aneuploidy screening
  8. Pregnancy
  9. Screening in the presence of a vanished twin: Nuchal translucency or combined screening test?
  10. The relationship between maternal body mass, smoking status and ethnicity and first trimester nuchal translucency thickness
  11. First and Second Trimester Markers of Fetal Aneuploidy in Pregnant Women with HIV Infection
  12. Maternal plasma levels of follistatin‐related gene protein in the first trimester of pregnancies with Down syndrome
  13. PAPP‐A and free ß‐hCG stability in first trimester serum using PerkinElmer AutoDELFIA® and DELFIA® Xpress systems
  14. Maternal serum screening marker levels in women with a previous aneuploidy pregnancy
  15. Is maternal renal disease a cause of elevated free β‐hCG in first trimester aneuploidy screening?
  16. The effect of Rhesus status on first‐trimester pregnancy screening markers free β human chorionic gonadotropin, pregnancy‐associated plasma protein‐A and nuchal translucency
  17. First trimester intact hCG as an early marker of trisomy 21: a promise unrecognised?
  18. Maternal serum ADAM12s in the late first trimester of pregnancies with Trisomy 21
  19. First‐trimester ADAM12s as early markers of trisomy 21: a promise still unfulfilled?
  20. ADAM12s in maternal serum as a potential marker of pre‐eclampsia
  21. Physiological distribution of placental growth factor and soluble Flt‐1 in early pregnancy
  22. First-trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes
  23. Low levels of maternal serum PAPP‐A in the first trimester and the risk of pre‐eclampsia
  24. First trimester screening for Down syndrome using free β hCG, total hCG and PAPP‐A: an exploratory study
  25. Aneuploidy screening in the first trimester
  26. Second‐trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre‐eclampsia
  27. First‐trimester ADAM12 and PAPP‐A as markers for intrauterine fetal growth restriction through their roles in the insulin‐like growth factor system
  28. CT ratios: parameter estimates are inconsistent with SURUSS publications?
  29. First Trimester Serum Screening
  30. ADAM12-s in coelomic fluid and maternal serum in early pregnancy
  31. Author's reply
  32. Predicting complications of pregnancy with first‐trimester maternal serum free‐βhCG, PAPP‐A and inhibin‐A
  33. Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy
  34. Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited
  35. Accuracy of Down syndrome risks produced in a first‐trimester screening programme incorporating fetal nuchal translucency thickness and maternal serum biochemistry
  36. Maternal serum activin A and inhibin A in trisomy 18 pregnancies at 10–14 weeks
  37. Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies
  38. Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester
  39. First trimester markers of trisomy 21 and the influence of maternal cigarette smoking status
  40. Maternal serum total hCG and free β‐hCG in the first trimester from trisomy 21 pregnancies
  41. Second‐trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome
  42. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities
  43. Maternal serum free ?-hCG and PAPP-A in fetal sex chromosome defects in the first trimester
  44. The influence of fetal sex in screening for Down syndrome in the second trimester using AFP and free ?-hCG
  45. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities
  46. The influence of smoking on maternal serum PAPP-A and free beta hCG levels in the first trimester of pregnancy
  47. BETWEEN-PREGNANCY BIOLOGICAL VARIABILITY OF MATERNAL SERUM ALPHA- FETOPROTEIN AND FREE BETA hCG: IMPLICATIONS FOR DOWN SYNDROME SCREENING IN SUBSEQUENT PREGNANCIES
  48. FREE BETA hCG SCREENING OF HYDROPIC AND NON-HYDROPIC TURNER SYNDROME PREGNANCIES
  49. The influence of gravidity on Down's syndrome screening with free beta hCG
  50. Authors' reply to Wierzbicki and Zimmermann
  51. Second‐trimester CA 125 and Down's syndrome
  52. Free α-subunit of human chorionic gonadotropin in Down syndrome
  53. Screening For Down's Syndrome. The Role Of Intact Hcg and Free Subunit Measurement